1
Clinical Trials associated with PEP-CMV Vaccine(Nationwide Children's Hospital)Phase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB).
PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51.
Funding Source - FDA OOPD
100 Clinical Results associated with PEP-CMV Vaccine(Nationwide Children's Hospital)
100 Translational Medicine associated with PEP-CMV Vaccine(Nationwide Children's Hospital)
100 Patents (Medical) associated with PEP-CMV Vaccine(Nationwide Children's Hospital)
100 Deals associated with PEP-CMV Vaccine(Nationwide Children's Hospital)